Bank Of America Corp Maxcyte, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Maxcyte, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 197,137 shares of MXCT stock, worth $699,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,137

Previous 154,335 27.73%

Holding current value

$699,836

Previous $604,000 26.82%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.68 - $5.06 $157,511 - $216,578	42,802 Added 27.73%	197,137 $766,000
Q2 2024 Aug 14, 2024	BUY	$3.63 - $5.0 $78,346 - $107,915	21,583 Added 16.26%	154,335 $604,000
Q1 2024 May 15, 2024	SELL	$3.94 - $5.38 $49,238 - $67,233	-12,497 Reduced 8.6%	132,752 $556,000
Q4 2023 Feb 14, 2024	BUY	$2.6 - $5.24 $194,688 - $392,371	74,880 Added 106.41%	145,249 $682,000
Q2 2023 Aug 14, 2023	SELL	$3.69 - $5.35 $61,283 - $88,852	-16,608 Reduced 19.09%	70,369 $322,000
Q1 2023 May 12, 2023	SELL	$4.03 - $5.89 $1.63 Million - $2.38 Million	-403,275 Reduced 82.26%	86,977 $430,000
Q4 2022 Feb 10, 2023	SELL	$4.92 - $7.4 $1.17 Million - $1.76 Million	-237,547 Reduced 32.64%	490,252 $2.68 Million
Q3 2022 Nov 14, 2022	BUY	$4.52 - $6.51 $3.14 Million - $4.53 Million	695,433 Added 2148.65%	727,799 $4.73 Million
Q2 2022 Aug 12, 2022	SELL	$3.59 - $6.81 $122,943 - $233,215	-34,246 Reduced 51.41%	32,366 $153,000
Q1 2022 May 16, 2022	BUY	$5.26 - $10.84 $97,125 - $200,160	18,465 Added 38.35%	66,612 $466,000
Q4 2021 Feb 08, 2022	BUY	$8.87 - $12.94 $404,126 - $589,559	45,561 Added 1761.83%	48,147 $491,000
Q3 2021 Nov 15, 2021	BUY	$12.21 - $17.2 $31,575 - $44,479	2,586 New	2,586 $31,000

Others Institutions Holding MXCT

# of Institutions

124

Shares Held

65.6M

Call Options Held

Put Options Held

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $361M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Maxcyte, Inc. Transaction History